



Evoke Pharma Announces Approval of GIMOTI® to Florida State Medicaid Program

June 15, 2022

SOLANA BEACH, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that the Florida Medicaid Pharmaceutical & Therapeutics Committee has approved adding GIMOTI, the Company's novel treatment solution meant to treat symptoms associated with acute and recurrent diabetic gastroparesis, to the Florida Medicaid Preferred Drug List (PDL) effective immediately.

To prescribe Gimoti under the plan, healthcare providers need to attest to the patient being at least 18 years of age, having a diagnosis of diabetic gastroparesis, and being unable to use oral metoclopramide. These criteria are typical for Gimoti coverage under state Medicaid programs and consistent with Company expectations for utility in helping patients who suffer from this debilitating disease. Patients taking oral metoclopramide are often unable to achieve relief due to a delay in gastric emptying and erratic absorption of oral medication. We believe many patients can benefit from the novel nasal delivery of Gimoti to treat symptoms such as nausea, vomiting and abdominal pain. The Florida Medicaid formulary and related programs provide healthcare to approximately 5 million beneficiaries.

With this addition, we are building a strong foundation and momentum for positive access to GIMOTI within Medicaid lives in the US. "We view this addition to the Florida Medicaid PDL as a win for patient access to this important medicine for diabetic gastroparesis patients, who have very limited options to obtain symptomatic relief. In a world where many new products are excluded from formularies and patient access is denied, this decision is a significant commercial milestone for GIMOTI," stated Matt D'Onofrio, MBA, Evoke Pharma's Chief Business Officer. "Medicaid approvals across various jurisdictions are one of the primary components of our business plan to increase GIMOTI access. With this addition, we believe we are steadily executing the right strategies to ensure that healthcare providers around the country have the option to make GIMOTI the standard of care for diabetic gastroparesis."

About Evoke Pharma, Inc.

Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.

Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis. Visit www.EvokePharma.com for more information.

Follow GIMOTI on Facebook: <https://www.facebook.com/GIMOTI-metoclopramide-nasal-spray-104672345100289>

Follow Evoke Pharma on Facebook: <https://www.facebook.com/Evoke-Pharma-Inc-131313647029724>

Follow Evoke Pharma on LinkedIn: <https://www.linkedin.com/company/evoke-pharma/>

About Gimoti™ (metoclopramide) nasal spray

GIMOTI is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.

Important Safety Information

WARNING: TARDIVE DYSKINESIA

- Metoclopramide can cause tardive dyskinesia (TD), a serious movement disorder that is often irreversible. The risk of developing TD increases with duration of treatment and total cumulative dosage.
- Discontinue GIMOTI in patients who develop signs or symptoms of TD. In some patients, symptoms may lessen or resolve after metoclopramide is stopped.
- Avoid treatment with metoclopramide (all dosage forms and routes of administration) for longer than 12 weeks because of the increased risk of developing TD with longer-term use.

GIMOTI is not recommended for use in:

- Pediatric patients due to the risk of developing tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates.
- Moderate or severe hepatic impairment (Child-Pugh B or C), moderate or severe renal impairment (creatinine clearance

less than 60 mL/minute), and patients concurrently using strong CYP2D6 inhibitors due to the risk of increased drug exposure and adverse reactions.

GIMOTI is contraindicated:

- In patients with a history of tardive dyskinesia (TD) or a dystonic reaction to metoclopramide.
- When stimulation of gastrointestinal motility might be dangerous (e.g., in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation).
- In patients with pheochromocytoma or other catecholamine-releasing paragangliomas. Metoclopramide may cause a hypertensive/pheochromocytoma crisis, probably due to release of catecholamines from the tumor.
- In patients with epilepsy. Metoclopramide may increase the frequency and severity of seizures.
- In patients with hypersensitivity to metoclopramide. Reactions have included laryngeal and glossal angioedema and bronchospasm.

Potential adverse reactions associated with metoclopramide include: Tardive dyskinesia (TD), other extrapyramidal effects (EPS), parkinsonism symptoms, motor restlessness, neuroleptic malignant syndrome (NMS), depression, suicidal ideation and suicide, hypertension, fluid retention, hyperprolactinemia, effects on the ability to drive and operate machinery. Most common adverse reactions (≥5%) for GIMOTI are: dysgeusia, headache, and fatigue. These are not all of the possible side effects of GIMOTI. Call your doctor for medical advice about whether you should take GIMOTI and the possible risk factors and side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Safe Harbor Statement

Evoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on the company’s current beliefs and expectations. These forward-looking statements include statements regarding: the potential benefits of GIMOTI for patients with diabetic gastroparesis; and Evoke’s ability to increase access to and awareness of GIMOTI. The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Evoke’s business, including, without limitation: Evoke’s and EVERSAN’s ability to successfully drive market demand for GIMOTI; Evoke’s ability to maintain Medicare coverage in various jurisdictions; the COVID-19 pandemic may continue to disrupt Evoke’s and EVERSAN’s business operations impairing the ability to commercialize GIMOTI and Evoke’s ability to generate any product revenue; Evoke’s dependence on third parties for the manufacture of GIMOTI; Evoke is entirely dependent on the success of GIMOTI; inadequate efficacy or unexpected adverse side effects relating to GIMOTI that could result in recalls or product liability claims; and other risks and uncertainties detailed in Evoke’s prior press releases and in the periodic reports it files with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Evoke undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Investor Contact:

Daniel Kontoh-Boateng
DKB Partners
Tel: 862-213-1398
dboateng@dkbpartners.net



Source: Evoke Pharma, Inc.